May 09, 2023 8:00am EDT Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
Apr 19, 2023 9:25am EDT Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development
Apr 11, 2023 8:10am EDT Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
Apr 03, 2023 8:00am EDT Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
Mar 30, 2023 5:37pm EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 22, 2023 8:05am EDT Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study